News
Sobi, Innate Pharma Partner to License Lacutamab in Cutaneous T-Cell Lymphoma
Under the agreement, Innate Pharma will conduct the TELLOMAK-3 Phase 3 trial in cutaneous T-cell lymphoma (CTCL), while Sobi will receive exclusive global commercialisation rights for lacutamab following a potential accelerated approval.
imphoenix82
- August 10, 2026
- 0 Comments
- 72 Views
-
